Structure via PubChem · Public domain (PubChem)
vorinostat
Sign in to saveAlso known as SAHA, suberoylanilide hydroxamic acid, SHH, octanedioic acid hydroxyamide phenylamide, Suberoylanilide hydroxamic acid, Octanedioic acid hydroxyamide phenylamide, suberanilohydroxamic acid
Vorinostat (rINN), also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Chemical data
- Formula
- C14H20N2O3
- Molecular weight
- 264.32 g/mol
- IUPAC name
- N'-hydroxy-N-phenyloctanediamide
- SMILES
- C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
- InChIKey
- WAEXFXRVDQXREF-UHFFFAOYSA-N
- XLogP
- 1.9
- Polar surface area
- 78.4 Ų
- H-bond donors
- 3
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2006
- Admin. routes
- oral
- Indications
- HIV infection, multiple myeloma, non-small cell lung carcinoma, lymphoma
via ChEMBL · EBI
Research
3,228 papers- Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.The Lancet. Oncology · 2018
- Vorinostat as potential antiparasitic drug.European review for medical and pharmacological sciences · 2020
- Repurposing Vorinostat for the Treatment of Disorders Affecting Brain.Neuromolecular medicine · 2021
- Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention.Drug discovery today · 2022
- Vorinostat for treatment-refractory bullous pemphigoid.Journal of the European Academy of Dermatology and Venereology : JEADV · 2023
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Has part
- oxygen
- Mass
- 264.147
- Has use
- medication
Show 6 more facts
- Commons category
- Vorinostat
- chemical formula
- C₁₄H₂₀N₂O₃
- subject has role
- histone deacetylase inhibitors
- medical condition treated
- mycosis fungoides
- canonical SMILES
- C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
- World Health Organisation international non-proprietary name
- vorinostat
via Wikidata · CC0
~4 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Development
- Mechanism of action
- Clinical trials
- Preclinical investigations
- See also
- References
- External links
Vorinostat (rINN), also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
Vorinostat is marketed under the name Zolinza ( ) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies. The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks.
Excerpted from Wikipedia’s “vorinostat” article, available under the CC BY-SA 4.0 licence.